Literature DB >> 10870037

Interaction between glucagon and human corticotropin-releasing hormone or vasopressin on ACTH and cortisol secretion in humans.

E Arvat1, B Maccagno, J Ramunni, M Maccario, R Giordano, F Broglio, F Camanni, E Ghigo.   

Abstract

OBJECTIVE: It is known that glucagon administration elicits ACTH and cortisol responses in humans, although this effect takes place after intramuscular or subcutaneous but not after the intravenous route of administration. The mechanisms underlying this stimulatory effect on corticotroph secretion are unknown but they are unrelated to glucose variations and stress-mediated actions. DESIGN AND METHODS: To throw further light on the stimulatory effect of i.m. glucagon on the pituitary-adrenal axis, using six normal young female volunteers (26-32 years, body mass index 19.7-22.5 kg/m(2)) we studied the interaction between glucagon (GLU; 0.017 mg/kg i.m.) and human corticotropin-releasing hormone (hCRH; 2.0 microg/kg i.v.) or vasopressin (AVP; 0.17 U/kg i.m.). The interactions between hCRH and AVP on the hypothalamo-pituitary-adrenal (HPA) axis and the GH response to GLU alone or combined with hCRH or AVP were also studied.
RESULTS: GLU i.m. administration elicited a clear increase in ACTH (peak vs baseline, means+/-s.e.m.: 11.6+/-3.3 vs 4.2+/-0.3 pmol/l, P<0.05), cortisol (613.5+/-65.6 vs 436.9+/-19.3 nmol/l, P<0.05) and GH levels (11.6+/-3.4 vs 3.3+/-0.7 microg/l, P<0.05). The ACTH response to GLU (area under the curve: 426.4+/-80.9 pmol/l per 120 min) was higher than that to AVP (206.3+/-38.8 pmol/l per 120 min, P<0.02) and that to hCRH (299.8+/-39.8 pmol/l per 120 min) although this latter difference did not attain statistical significance. The GLU-induced cortisol response (28336.9+/-2430.7 nmol/l per 120 min) was similar to those after hCRH (24099.2+/-2075.2 nmol/l per 120 min) and AVP (21808.7+/-1948.2 nmol/l per 120 min). GLU and hCRH had an additive effect on ACTH (964.9+/-106.6 pmol/l per 120 min, P<0.02) and a less than additive effect on cortisol levels (35542.5+/-2720. 2 nmol/l per 120 min). Similarly, GLU and AVP had an additive effect on ACTH (825.6+/-139.6 pmol/l per 120 min, P<0.02) and an effect less than additive on cortisol levels (33059.2+/-1965.3 nmol/l per 120 min). The effects of GLU co-administered with hCRH or AVP were similar to those of the combined administration of hCRH and AVP on ACTH (906. 0+/-152.7 pmol/l per 120 min) and cortisol (34383.5+/-1669.2 nmol/l per 120min) levels. The GH response to GLU was not modified by hCRH or AVP.
CONCLUSIONS: These results show that i.m. glucagon administration is a provocative stimulus of ACTH and cortisol secretion, at least as potent as hCRH and AVP. The ACTH-releasing effect of i.m. glucagon is not mediated by selective CRH or AVP stimulation but the possibility that both neurohormones play a role could be hypothesized.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10870037     DOI: 10.1530/eje.0.1430099

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  14 in total

1.  Substrate metabolism, hormone and cytokine levels and adipose tissue signalling in individuals with type 1 diabetes after insulin withdrawal and subsequent insulin therapy to model the initiating steps of ketoacidosis.

Authors:  Thomas S Voss; Mikkel H Vendelbo; Ulla Kampmann; Steen B Pedersen; Thomas S Nielsen; Mogens Johannsen; Mads V Svart; Niels Jessen; Niels Møller
Journal:  Diabetologia       Date:  2018-12-01       Impact factor: 10.122

2.  Clinical characteristics, timing of peak responses and safety aspects of two dosing regimens of the glucagon stimulation test in evaluating growth hormone and cortisol secretion in adults.

Authors:  Kevin C J Yuen; Beverly M K Biller; Laurence Katznelson; Sharon A Rhoads; Michelle H Gurel; Olivia Chu; Valentina Corazzini; Kellie Spiller; Murray B Gordon; Roberto Salvatori; David M Cook
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

3.  Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic-pituitary-adrenal axes in adults: results from a prospective randomized multicenter study.

Authors:  Amir H Hamrahian; Kevin C J Yuen; Murray B Gordon; Karen J Pulaski-Liebert; James Bena; Beverly M K Biller
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

4.  Glucagon administration elicits blunted GH but exaggerated ACTH response in obesity.

Authors:  F Tassone; S Grottoli; R Rossetto; B Maccagno; C Gauna; R Giordano; E Ghigo; M Maccario
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

5.  Effects of gender, body weight, and blood glucose dynamics on the growth hormone response to the glucagon stimulation test in patients with pituitary disease.

Authors:  Jessica R Wilson; Andrea L Utz; Jessica K Devin
Journal:  Growth Horm IGF Res       Date:  2015-12-08       Impact factor: 2.372

6.  A significant proportion of thalassemia major patients have adrenal insufficiency detectable on provocative testing.

Authors:  Karen E Huang; Steven D Mittelman; Thomas D Coates; Mitchell E Geffner; John C Wood
Journal:  J Pediatr Hematol Oncol       Date:  2015-01       Impact factor: 1.289

7.  Pegvisomant-primed glucagon stimulation test in assessing GH reserve and GH/IGF kinetics in adults suspected of GH deficiency.

Authors:  Kevin C J Yuen; Jan Frystyk; Sharon A Rhoads; Martin Bidlingmaier
Journal:  Pituitary       Date:  2016-02       Impact factor: 4.107

Review 8.  Investigation of the Hypothalamo-pituitary-adrenal (HPA) axis: a contemporary synthesis.

Authors:  Zuleyha Karaca; Ashley Grossman; Fahrettin Kelestimur
Journal:  Rev Endocr Metab Disord       Date:  2021-03-26       Impact factor: 6.514

9.  The stimulatory effects of glucagon on cortisol and GH secretion occur independently from FGF-21.

Authors:  Ilyas Akkar; Zuleyha Karaca; Serpil Taheri; Kursad Unluhizarci; Aysa Hacioglu; Fahrettin Kelestimur
Journal:  Endocrine       Date:  2021-09-25       Impact factor: 3.633

10.  Glucagon stimulation testing in assessing for adult growth hormone deficiency: current status and future perspectives.

Authors:  Kevin C J Yuen
Journal:  ISRN Endocrinol       Date:  2011-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.